Trail, Fas Ligand, Tnf and Tlr3 in Cancer
暫譯: 癌症中的Trail、Fas配體、Tnf和Tlr3

Name: Trail, Fas Ligand, Tnf and Tlr3 in Cancer
Price: 6584 TWD
Availability: OnlineOnly
Author: Micheau, Olivier
ISBN: 3319860062

Micheau, Olivier

出版商: Springer
出版日期: 2018-08-12
售價: $6,930
貴賓價: 9.5 折 $6,584
語言: 英文
頁數: 317
裝訂: Quality Paper - also called trade paper
ISBN: 3319860062
ISBN-13: 9783319860060

海外代購書籍(需單獨結帳)

商品描述

This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.

商品描述(中文翻譯)

本卷提供了對於死亡受體/TLR3 信號調控在癌症中的當前理解。死亡受體，包括 TRAIL-R1、TRAIL-R2、Fas 和 TNF-RI，由於其觸發細胞凋亡的能力以及促進免疫系統消除癌細胞的作用，已被視為癌症治療的重要治療靶點，程度各異。然而，越來越多的證據表明，這些受體中的某些可能也會促進腫瘤形成，或者像 TLR3 這樣的新成員可能因其表現出類似死亡受體的能力而成為癌症治療的目標。

作者簡介

Dr. Olivier Micheau is a research director of the INSERM (French National Institute of Health), UMR1231. He received his PhD in Biochemistry and Molecular and Cellular Biology in 1999 from the University of Burgundy, France. He next moved as a post-doctoral fellow in Jurg Tschopp's laboratory in Epalinges, Switzerland, from 1999 to 2003, where he elucidated the molecular mechanisms underlying TNFR1's dual signaling ability. He described for the first time TNFR1 cytosolic pro-apoptotic complex II. In 2003 he joined the INSERM unit U517 headed by Professor E. Solary in Dijon, France, as an INSERM researcher. Member of several scientific councils, including INSERM CSS3 (2012-2016) and Fondation ARC pour la recherche sur le cancer, a French Charity (since 2015), he is also Associate Editor of the British Journal of Pharmacology since 2012. His scientific interest focuses on TRAIL receptor signaling and its use in cancer therapy.

作者簡介(中文翻譯)

奧利維耶·米肖博士是法國國家健康研究院（INSERM）UMR1231的研究主任。他於1999年在法國勃艮第大學獲得生物化學及分子與細胞生物學博士學位。隨後，他於1999年至2003年在瑞士埃帕林熱斯的尤爾格·茨霍普實驗室擔任博士後研究員，揭示了TNFR1雙重信號能力的分子機制。他首次描述了TNFR1細胞質中的促凋亡複合體II。2003年，他作為INSERM研究員加入了由E. Solary教授領導的法國第戎INSERM單位U517。他是多個科學委員會的成員，包括INSERM CSS3（2012-2016）和法國癌症研究基金會（Fondation ARC pour la recherche sur le cancer，自2015年起），自2012年以來也是《英國藥理學雜誌》的副編輯。他的科學興趣集中在TRAIL受體信號傳導及其在癌症治療中的應用。